English

OEM Supply Doxycycline Hyclate 75 Mg - Captopril – CPF

OEM Supply Doxycycline Hyclate 75 Mg - Captopril – CPF Featured Image
  • OEM Supply Doxycycline Hyclate 75 Mg - Captopril – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We take pleasure in a really excellent name amongst our shoppers for our exceptional product or service excellent, competitive rate and also the greatest services for Favipiravir, Doxycycline Hyclate 75 Mg, Doxycycline Hyclate, If you are interested in any of our products and services, please don't hesitate to contact us. We are ready to reply you within 24 hours after receipt of your request and to create mutual un-limited benefits and business in near future.
OEM Supply Doxycycline Hyclate 75 Mg - Captopril – CPF Detail:

Description

Captopril (SQ-14534) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE).

In Vitro

Captopril (SQ-14534) has been shown to have similar morbidity and mortality benefits to those of diuretics and beta-blockers in hypertensive patients. Captopril (SQ-14534) has been shown to delay the progression of diabetic nephropathy, and enalapril and lisinopril prevent the development of nephropathy in normoalbuminuric patients with diabetes[1]. An equimolar ratio of the cis and trans states of Captopril (SQ-14534) exists in solution and that the enzyme selects only the trans state of the inhibitor that presents architectural and stereoelectronic complementarity with its substrate binding groove[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase
NCT03179163 Penn State University|National Heart, Lung, and Blood Institute (NHLBI) Hypertension,Essential July 20, 2016

Phase 1|Phase 2
NCT03660293 Tanta University Diabetes Mellitus, Type 1 April 1, 2017

Not Applicable
NCT03147092 Centro Neurológico de Pesquisa e Reabiitação, Brazil Hypertension|Blood Pressure February 1, 2018

Early Phase 1
NCT00252317 Rigshospitalet, Denmark Aortic Stenosis November 2005

Phase 4
NCT02217852 West China Hospital Hypertension August 2014

Phase 4
NCT01626469 Brigham and Women´s Hospital Type 2 Diabetes Mellitus May 2012

Phase 1|Phase 2
NCT00391846 AstraZeneca Heart Failure|Ventricular Dysfunction, Left October 2006

Phase 4
NCT00240656 Hebei Medical University Hypertension, Pulmonary October 2005

Phase 1
NCT00086723 Northwestern University|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific July 2003

Phase 1|Phase 2
NCT00663949 Shiraz University of Medical Sciences Diabetic Nephropathy February 2006

Phase 2|Phase 3
NCT01437371 University Hospital, Clermont-Ferrand|Servier|LivaNova Heart Failure August 2011

Phase 3
NCT04288700 Ain Shams University Infantile Hemangioma October 1, 2019

Phase 4
NCT00223717 Vanderbilt University|Vanderbilt University Medical Center Hypertension January 2001

Phase 1
NCT02770378 University of Ulm|Reliable Cancer Therapies|Anticancer Fund, Belgium Glioblastoma November 2016

Phase 1|Phase 2
NCT01761916 Instituto Materno Infantil Prof. Fernando Figueira Preeclampsia January 2013

Phase 4
NCT01545479 Instituto de Cardiologia do Rio Grande do Sul Renal Disease January 2010

Phase 4
NCT00935805 Hospital de Clinicas de Porto Alegre|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil Diabetes Mellitus|Arterial Hypertension July 2006

NCT00742040 The Hospital for Sick Children Heart Disease August 2008

Phase 2
NCT03613506 Wuhan University Radiotherapy Side Effect|Taking Captopril October 25, 2018

Phase 2
NCT00004230 Northwestern University|National Cancer Institute (NCI) Cancer October 1999

Phase 3
NCT00660309 Novartis Type 2 Diabetes Mellitus April 2008

Phase 4
NCT00292162 NHS Greater Glasgow and Clyde Chronic Heart Failure|Atrial Fibrillation January 2007

Not Applicable
NCT01271478 Coordinación de Investigación en Salud, Mexico Inflammation|End-stage Renal Disease August 2009

Phase 4
NCT04193137 Chongqing Medical University Primary Aldosteronism November 30, 2019

NCT00155064 National Taiwan University Hospital Hyperaldosteronism July 2002

Phase 4
NCT01292694 Vanderbilt University|Vanderbilt University Medical Center Hypertension|Pure Autonomic Failure|Multiple System Atrophy March 2011

Phase 1
NCT00917345 National Taiwan University Hospital|Novartis Primary Aldosteronism January 2008

NCT00077064 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Lung Cancer|Pulmonary Complications|Radiation Fibrosis June 2003

Phase 2

Storage

Powder

-20°C

 3 years
 

4°C

 2 years
In solvent

-80°C

 6 months
 

-20°C

 1 month

Chemical structure

Captopril

2018 GMP-2
原料药GMP证书201811（captopril ,thalidomide etc）
GMP-of-PMDA-in-Chanyoo-平成28年08月03日　Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation

Product detail pictures:

OEM Supply Doxycycline Hyclate 75 Mg - Captopril – CPF detail pictures

Related Product Guide:
We take "customer-friendly, quality-oriented, integrative, innovative" as objectives. "Truth and honesty" is our management ideal for OEM Supply Doxycycline Hyclate 75 Mg - Captopril – CPF , The product will supply to all over the world, such as: Accra, Chile, Nigeria, Our Company policy is "quality first, to be better and stronger, sustainable development" . Our pursuit goals is "for society, customers, employees, partners and enterprises to seek reasonable benefit". We aspirate to do cooperate with all different the auto parts manufacturers, repair shop, auto peer , then create a beautiful future! Thank you for taking time to browse our website and we would welcome any suggestions you may have that can help us to improve our site.
    • This company has a lot of ready-made options to choose and also could custom new program according to our demand, which is very nice to meet our needs.
    5 Stars By Norma from Johor - 2018.06.18 17:25
    The factory workers have rich industry knowledge and operational experience, we learned a lot in working with them,we are extremely grateful that we can encount a good company has excellent wokers.
    5 Stars By Olive from Hamburg - 2018.02.21 12:14
    Write your message here and send it to us

    Products categories